Akouos (Akouos) EBIT : $-93.22 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Akouos EBIT?

Akouos's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2022 was $-20.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2022 was $-93.22 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Akouos's annualized ROC % for the quarter that ended in Sep. 2022 was -149.19%. Akouos's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -168.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Akouos's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -26.11%.

Akouos EBIT Historical Data

The historical data trend for Akouos's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos EBIT Chart

Akouos Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

EBIT

-7.42

-23.88

-48.88

-86.82

Akouos Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT	Get a 7-Day Free Trial											-22.91	-24.98	-27.03	-21.00	-20.20

Competitive Comparison of Akouos's EBIT

For the Biotechnology subindustry, Akouos's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akouos's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akouos's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Akouos's EV-to-EBIT falls into.

Akouos EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-93.22 Mil.

Akouos (NAS:AKUS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Akouos's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-80.816 * ( 1 - 0% )	/	( (52.943	+	55.398)	/ 2 )
=	-80.816	/	54.1705
=	-149.19 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	244.537	-	11.268	-	( 192.895	-	max(0, 14.59	-	194.916	+	192.895	))
=	52.943

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	225.509	-	5.705	-	( 169.328	-	max(0, 10.087	-	174.493	+	169.328	))
=	55.398

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Akouos's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-80.816	/	( ( (47.142 + max(-11.821, 0))	+	(48.539 + max(-4.137, 0)) )	/	2 )
=	-80.816	/	( ( 47.142	+	48.539 )	/	2 )
=	-80.816	/	47.8405
=	-168.93 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.021)	-	(11.268	+	0	+	2.574)
=	-11.821

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.165)	-	(5.705	+	0	+	3.597)
=	-4.137

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Akouos's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2022 )
	=	-93.215	/	357.056
	=	-26.11 %

Akouos EBIT Related Terms

Thank you for viewing the detailed overview of Akouos's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Akouos (Akouos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 200, Boston, MA, USA, 02210

Website

https://www.akouos.com

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.

Executives

Kearny Acquisition Corp	10 percent owner	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman	officer: Chief Operating Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi	officer: Chief Financial Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi	10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p.	10 percent owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston	director, 10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102